Document:

Form of Notice of Performance-Based Restricted Stock Unit Grant - Employee

 Exhibit 10.6 
 [Employee] 
 Notice of Performance-Based Restricted Stock Unit Grant

  

			
	Participant:	  	[Participant Name]
		
	Corporation:	  	CoreLogic, Inc.
		
	Notice:	  	You have been granted the following Performance-Based Restricted Stock Units (“Performance-Based RSUs”) in accordance with the terms of the Plan and the Performance-Based
Restricted Stock Unit Award Agreement attached hereto.
		
	Type of Award:	  	Performance-Based RSUs
		
	Plan:	  	The CoreLogic, Inc. 2011 Performance Incentive Plan
		
	Grant:	  	Date of Grant: [Grant Date]
		  	Number of Performance-Based RSUs: [Number of RSUs Granted]
		
	Vesting:	  	Subject to the terms of the Plan and this Agreement, the vesting and payment of the Performance-Based RSUs shall be subject to the attainment of the Performance Measures set forth
below. The vesting schedule set forth below requires the Participant’s continued employment or service through each applicable vesting date as a condition to the vesting of any of the Shares underlying the Performance-Based RSUs. Except as
provided in Sections 4 and 5 of this Agreement, employment or service for only a portion of the vesting period, even if a substantial portion, will not entitle the Participant to any proportionate vesting or avoid or mitigate a termination of rights
and benefits upon or following a termination of employment or services as provided in Section 4 below or under the Plan.
		
	Performance Period:	  	The performance period for the Performance-Based RSUs shall commence on January 1 and end on December 31 (the “Performance Period”).
		
		  	Performance Measures
		
		  	 [Performance Measures to be inserted here]

			
		
		  	Forfeiture
		
		  	Any Shares underlying the Performance-Based RSUs that have not become vested and payable following the end of the Performance Period shall be immediately forfeited.
		
		  	Payment
		
		  	In addition to the continued employment requirements set forth above and in Section 4 of this Agreement, in order to receive payment of any Shares underlying the Performance-Based
RSUs which have become vested and payable based on the attainment of the Performance Measures set forth above (but not any Shares underlying Performance-Based RSUs which become vested and payable in connection with a change of control or other
corporate transaction as described in Section 5 of the Performance-Based Restricted Stock Unit Award Agreement attached hereto), the Participant must either (i) remain continuously employed through, and not have experienced a Termination prior to,
the date the Shares are paid in accordance with Section 6 of this Agreement or (ii) have experienced a Termination (as defined in Appendix A attached hereto) due to his or her death, Disability (as defined in Appendix A attached hereto), Normal
Retirement (as defined in the Performance-Based Restricted Stock Unit Award Agreement attached hereto) or a Termination described in Section 5(c) prior to the date the Shares are paid in accordance with Section 6 of this Agreement. In no event,
except for vesting in connection with a change of control or other corporate transaction as described in Section 5 of the Performance-Based Restricted Stock Unit Award Agreement attached hereto), shall any Performance-Based RSUs be considered to
have been earned unless and until such continued employment requirement is satisfied. Any Performance-Based RSUs which do not become payable as a result of the foregoing payment restriction shall be immediately forfeited on the date of the
Participant’s Termination.
		
	Rejection:	  	If you wish to accept this Performance-Based RSU Award, please access Fidelity NetBenefits® at www.netbenefits.com and follow the steps outlined under the “Accept
Grant” link at any time within forty-five (45) days after the Date of Grant. If you do not accept your grant via Fidelity NetBenefits® within forty-five (45) days after the Date of Grant, you will have rejected this Performance-Based RSU
Award.

  

  
 - 2 -

 [Employee] 
 Performance-Based Restricted Stock Unit Award Agreement 
 This
Performance-Based Restricted Stock Unit Award Agreement (this “Agreement”), dated as of the Date of Grant set forth in the Notice of Performance-Based Restricted Stock Unit Grant attached hereto (the “Grant Notice”), is made
between CoreLogic, Inc. (the “Corporation”) and the Participant set forth in the Grant Notice. The Grant Notice is included in and made part of this Agreement. 
 1. Definitions. 
 Certain capitalized terms are defined in the Grant
Notice, herein or in the attached Appendix A. Capitalized terms used but not defined in the Grant Notice, herein or in the attached Appendix A have the meaning assigned to such terms in the Plan. 

2. Grant of the Performance-Based RSUs. 
 Subject to the provisions of this Agreement and the provisions of the Plan, the Corporation hereby grants to the Participant, pursuant to the Plan, a right to receive the number of shares of Common Stock
(“Shares”) set forth in the Grant Notice (the “Performance-Based RSUs”). 
 3. Dividend Equivalents.

 Each Performance-Based RSU shall accrue Dividend Equivalents (as defined below) with respect to dividends that would
otherwise be paid on the Share underlying such Performance-Based RSU during the period from the Grant Date to the earlier of the date such Share is paid in accordance with this Agreement or the date the Share is forfeited pursuant to the terms of
this Agreement. As of any date in this period that the Corporation pays an ordinary cash dividend on its Common Stock, the Corporation shall credit the Participant with an additional number of Performance-Based RSUs equal to (i) the per share
cash dividend paid by the Corporation on its Common Stock on such date, multiplied by (ii) the total number of Performance-Based RSUs subject to the award as of the related dividend payment record date (including any Dividend Equivalents
previously credited hereunder), divided by (iii) the fair market value (as determined in accordance with the terms of the Plan) of a share of Common Stock on the date of payment of such dividend. Any Performance-Based RSUs credited pursuant to
the foregoing provisions of this Section 3 shall be subject to the attainment of the same Performance Measures applicable to the original Performance-Based RSUs to which they relate, and shall otherwise be subject to the same vesting, payment,
delivery and other terms, conditions and restrictions as the original Performance-Based RSUs to which they relate. Any such crediting of Dividend Equivalents shall be conclusively determined by the Administrator. No crediting of Performance-Based
RSUs shall be made pursuant to this Section 3 with respect to any Performance-Based RSUs which, as of such record date, have either been delivered or terminated pursuant to the Plan or this Agreement. For purposes of this Agreement,
“Dividend Equivalents” means the equivalent value (in cash or Shares) of dividends that would otherwise be paid on the Shares subject to the Performance-Based RSUs but that have not been issued or delivered. 

4. Vesting and Payment; Termination. 
 The Performance-Based RSUs shall vest and become payable subject to the attainment of the Performance Measures as set forth in the Grant Notice. Subject to the terms of the Plan, the remaining provisions
of this Section 4 and Section 5(b), all Performance-Based RSUs which have not become vested and payable prior to the date of the Participant’s Termination shall be immediately forfeited. Notwithstanding the foregoing to the contrary,
in the event of the Participant’s Termination due to his or her death, Disability or, except as provided in Section 5(b), Normal Retirement, in each case during the Performance Period and prior to the Shares underlying the
Performance-Based RSUs becoming vested and payable, then the Shares underlying the Performance-Based RSUs shall remain outstanding and shall be eligible to become vested and payable on a prorated basis such that the number of such Shares that shall
become vested and payable as of the conclusion of the Performance Period shall equal (i) the number of such Shares that would have vested as of the conclusion of the Performance Period based on the attainment of the Performance Measures set
forth in the Grant Notice or in 

  
 - 3 -

 
connection with a change of control or other corporate transaction as provided in Section 5(a) (assuming no termination of employment had occurred), multiplied by (ii) a fraction, the
numerator of which shall be the number of whole months during the Performance Period the Participant was employed by the Corporation or one of its Affiliates (as defined in Appendix A attached hereto), and the denominator of which shall be the
number of whole months in the Performance Period (provided that the Administrator may, in its sole discretion, provide for vesting of the full number of Shares determined under the foregoing clause (i)). Any such Shares that become vested and
payable shall be paid (together with Shares comprising all accrued Dividend Equivalents with respect to such Shares) to the Participant at the same time as specified in Section 5 or Section 6, as applicable. Any such Shares that have not
become vested and payable following the end of the Performance Period set forth in the Grant Notice shall be immediately forfeited. The vesting and payment provided for in this Section 4(a) in connection with a Termination due to the
Participant’s Disability or Normal Retirement is subject to the condition that the Participant shall have signed a separation agreement in the form established by the Corporation within 21 days (or such longer period of time required by
applicable law) following his or her Termination and such separation agreement is not subsequently revoked. 
 For purposes of this Agreement,
“Normal Retirement” means Termination of the Participant, other than for Cause (as defined in Appendix A attached hereto), after the Participant has reached 62 years of age. 

5. Change in Control. 
 (a) In the event of a corporate transaction described in 7.2 of the Plan (which generally includes transactions that the Corporation does not survive or does not survive as a public company in respect of
its Common Stock) in which the Administrator does not make a provision for the substitution, assumption, exchange or other continuation or settlement of the Performance-Based RSUs or (unless the Administrator has provided for the termination of the
award) the award would otherwise not continue in accordance with its terms in the circumstances, the Performance Period shall be shortened so that such period terminates prior to such transaction as determined by the Administrator (any such
shortened Performance Period, the “Shortened Performance Period”). The Participant shall be entitled to vesting of the number of Shares subject to the Performance-Based RSUs (or the equivalent fair market value thereof, as determined by
the Administrator, in cash) equal to the greater of (a) 100% of the total number of Performance-Based RSUs set forth in the Grant Notice or (b) the number of Performance RSUs that would have vested in accordance with the terms hereof based
on the Corporation’s actual performance for the Shortened Performance Period as determined using the Performance Measures set forth in the Grant Notice (assuming that such performance levels had been achieved for the entire Performance Period).
Notwithstanding anything to the contrary in the Plan or this Agreement, any Shares underlying the Performance-Based RSUs that become vested and payable in connection with the transaction as described above shall be paid (together with any Shares
comprising all accrued Dividend Equivalents with respect to such Shares) to the Participant as soon as practicable, but in no event later than 74 days following the date of such transaction. Any Shares underlying Performance-Based RSUs that have
been forfeited prior to the date of the transaction as described above shall not be eligible to become vested or payable in connection with any such transaction. 
 (b) In the event the Participant is Terminated by the Corporation or an Affiliate (including any successor to such entity) without Cause upon or at any time following a Change in Control and prior to the
payment or other forfeiture of the Performance-Based RSUs, then the Shares underlying the Performance-Based RSUs shall remain outstanding such that the number of such Shares that shall become vested and payable as of the conclusion of the
Performance Period shall equal the greater of (a) 100% of the total number of Performance-Based RSUs set forth in the Grant Notice or (b) the number of Performance RSUs that would have vested in accordance with the terms hereof based on
the Corporation’s actual performance for the Performance Period as determined using the Performance Measures set forth in the Grant Notice (assuming no termination of employment had occurred). In the event that the Participant would otherwise
be entitled to accelerated vesting of the Performance-Based RSUs in connection with his or her Termination under both Section 4 and this Section 5(b), the provisions of this Section 5(b) will apply, and the Participant will not be
entitled to any accelerated vesting under Section 4 with respect to such Termination. Any Shares underlying the Performance-Based RSUs that become vested and payable pursuant to this Section 5(b) shall be paid (together with any Shares
comprising all accrued 

  
 - 4 -

 
Dividend Equivalents with respect to such Shares) as provided in Section 6. Any Shares underlying Performance-Based RSUs that have been forfeited prior to the date of the Termination without
Cause as described above shall not be eligible to become vested or payable in connection with any such Termination. The vesting and payment provided for in this Section 5(b) in connection with the Participant’s Termination without Cause is
subject to the condition that the Participant shall have signed a separation agreement in the form established by the Corporation within 21 days (or such longer period of time required by applicable law) following his or her Termination and such
separation agreement is not subsequently revoked. 
 6. Payment of Shares. 

Except as otherwise provided herein, the Shares underlying the Performance-Based RSUs which have become vested and payable based on the
attainment of the Performance Measures set forth in the Grant Notice, together with Shares comprising all accrued Dividend Equivalents with respect to such Shares, shall be paid by the Corporation to the Participant as soon as reasonably
practicable, but in no event later than 74 days, following the end of the Performance Period set forth in the Grant Notice. Any Shares underlying the Performance-Based RSUs that have not become vested and payable following the end of the Performance
Period shall be forfeited as of the last day of the Performance Period. The Participant shall have no rights to receive payment of any Shares, whether pursuant to this Section 6 or any other provision of this Agreement, with respect to
Performance-Based RSUs that have been forfeited or cancelled, or for which Shares have previously been delivered. No fractional Shares shall be paid pursuant to this Section 6 or any other provision of this Agreement, and the Shares otherwise
payable shall be rounded down to the nearest whole number of Shares. 
 7. No Ownership Rights Prior to Issuance of
Shares. 
 Neither the Participant nor any other person shall become the beneficial owner of the Shares underlying the
Performance-Based RSUs, nor have any rights to dividends (other than rights to Dividend Equivalents pursuant to Section 3) or other rights as a stockholder with respect to any such Shares, until and after such Shares have been actually issued
to the Participant and transferred on the books and records of the Corporation or its agent in accordance with the terms of the Plan and this Agreement. 
 8. Detrimental Activity. 
 (a) Notwithstanding any other provisions of this
Agreement to the contrary, if at any time prior to the delivery of Shares with respect to the Performance-Based RSUs, the Participant engages in Detrimental Activity (as defined below), such Performance-Based RSUs shall be cancelled and rescinded
without any payment or consideration therefor. The determination of whether the Participant has engaged in Detrimental Activity shall be made by the Administrator in its good faith discretion, and the payment of Shares with respect to the
Performance-Based RSUs shall be suspended pending resolution to the Administrator’s satisfaction of any investigation of the matter. 
 (b) For purposes of this Agreement, “Detrimental Activity” means at any time (i) using information received during the Participant’s employment with the Corporation and/or its
Subsidiaries, Affiliates and predecessors in interest relating to the business affairs of the Corporation or any such Subsidiaries, Affiliates or predecessors in interest, in breach of the Participant’s express or implied undertaking to keep
such information confidential; (ii) directly or indirectly persuading or attempting to persuade, by any means, any employee of the Corporation or any of its Subsidiaries or Affiliates to breach any of the terms of his or her employment with
Corporation, its Subsidiaries or its Affiliates; (iii) directly or indirectly making any statement that is, or could be, disparaging of the Corporation or any of its Subsidiaries or Affiliates, or any of their respective employees (except to
the extent necessary to respond truthfully to any inquiry from applicable regulatory authorities or to provide information pursuant to legal process); (iv) directly or indirectly engaging in any illegal, unethical or otherwise wrongful activity
that is, or could be, substantially injurious to the financial condition, reputation or goodwill of the Corporation or any of its Subsidiaries or Affiliates; or (v) directly or indirectly engaging in an act of misconduct such as, embezzlement,
fraud, dishonesty, nonpayment of any obligation owed to the Corporation or any of its Subsidiaries or Affiliates, breach of fiduciary duty or disregard or violation of rules, policies or procedures of the Corporation or any of its Subsidiaries or
Affiliates, an unauthorized disclosure of any trade secret or confidential 

  
 - 5 -

 
information of the Corporation or any of its Subsidiaries or Affiliates, any conduct constituting unfair competition, or inducing any customer to breach a contract with the Corporation or any of
its Subsidiaries or Affiliates, in each case as determined by the Administrator in its good faith discretion. 
 9. No Right
to Continued Employment. 
 None of the Performance-Based RSUs nor any terms contained in this Agreement shall confer upon
the Participant any express or implied right to be retained in the employ of the Corporation or any Subsidiary or Affiliate for any period, nor restrict in any way the right of the Corporation or any Subsidiary or any Affiliate, which right is
hereby expressly reserved, to terminate the Participant’s employment at any time for any reason. For the avoidance of doubt, this Section 9 is not intended to amend or modify any other agreement, including any employment agreement, that
may be in existence between the Participant and the Corporation or any Subsidiary or Affiliate. 
 10. The Plan.

 In consideration for this grant, the Participant agrees to comply with the terms of the Plan and this Agreement. This
Agreement is subject to all the terms, provisions and conditions of the Plan, which are incorporated herein by reference, and to such regulations as may from time to time be adopted by the Administrator. In the event of any conflict between the
provisions of the Plan and this Agreement, the provisions of the Plan shall control, and this Agreement shall be deemed to be modified accordingly, provided that the provisions of Section 4, Section 5 and Section 6 of this Agreement
shall control over any conflicting payment provisions of the Plan. The Plan and the prospectus describing the Plan can be found on Fidelity NetBenefits® at www.netbenefits.com under Plan Information and Documents. A paper copy of the Plan
and the prospectus shall be provided to the Participant upon the Participant’s written request to the Corporation at CoreLogic, Inc., 4 First American Way, Santa Ana, California 92707, Attention: Incentive Compensation Plan Administrator, or
such other address as the Corporation may from time to time specify. 
 11. Compliance with Laws and Regulations.

 (a) The Performance-Based RSUs and the obligation of the Corporation to sell and deliver Shares hereunder shall be subject in
all respects to (i) all applicable Federal and state laws, rules and regulations and (ii) any registration, qualification, approvals or other requirements imposed by any government or regulatory agency or body which the Administrator
shall, in its discretion, determine to be necessary or applicable. Moreover, the Corporation shall not deliver any certificates for Shares to the Participant or any other person pursuant to this Agreement if doing so would be contrary to applicable
law. If at any time the Corporation determines, in its discretion, that the listing, registration or qualification of Shares upon any national securities exchange or under any state or Federal law, or the consent or approval of any governmental
regulatory body, is necessary or desirable, the Corporation shall not be required to deliver any certificates for Shares to the Participant or any other person pursuant to this Agreement unless and until such listing, registration, qualification,
consent or approval has been effected or obtained, or otherwise provided for, free of any conditions not acceptable to the Corporation. 
 (b) It is intended that the Shares received in respect of the Performance-Based RSUs shall have been registered under the Securities Act. If the Participant is an “affiliate” of the Corporation,
as that term is defined in Rule 144 under the Securities Act (“Rule 144”), the Participant may not sell the Shares received except in compliance with Rule 144. Certificates representing Shares issued to an “affiliate” of the
Corporation may bear a legend setting forth such restrictions on the disposition or transfer of the Shares as the Corporation deems appropriate to comply with Federal and state securities laws. 

(c) If, at any time, the Shares are not registered under the Securities Act, and/or there is no current prospectus in effect under the
Securities Act with respect to the Shares, the Participant shall execute, prior to the delivery of any Shares to the Participant by the Corporation pursuant to this Agreement, an agreement (in such form as the Corporation may specify) in which the
Participant represents and warrants that the Participant is purchasing or acquiring the Shares acquired under this Agreement for the Participant’s own account, for investment 

  
 - 6 -

 
only and not with a view to the resale or distribution thereof, and represents and agrees that any subsequent offer for sale or distribution of any kind of such Shares shall be made only pursuant
to either (i) a registration statement on an appropriate form under the Securities Act, which registration statement has become effective and is current with regard to the Shares being offered or sold, or (ii) a specific exemption from the
registration requirements of the Securities Act, but in claiming such exemption the Participant shall, prior to any offer for sale of such Shares, obtain a prior favorable written opinion, in form and substance satisfactory to the Corporation, from
counsel for or approved by the Corporation, as to the applicability of such exemption thereto. 
 12. Notices.

 All notices by the Participant or the Participant’s assignees shall be addressed to CoreLogic, Inc., 4 First American
Way, Santa Ana, California 92707, Attention: Incentive Compensation Plan Administrator, or such other address as the Corporation may from time to time specify. All notices to the Participant shall be addressed to the Participant at the
Participant’s address in the Corporation’s records. 
 13. Severability. 

In the event any provision of this Agreement shall be held illegal or invalid for any reason, the illegality or invalidity shall not
affect the remaining parts of this Agreement, and this Agreement shall be construed and enforced as if the illegal or invalid provision had not been included. 
 14. Other Plans. 
 The Participant acknowledges that any income derived
from the Performance-Based RSUs shall not affect the Participant’s participation in, or benefits under, any other benefit plan or other contract or arrangement maintained by the Corporation or any Subsidiary or Affiliate. Performance-Based RSUs
and Dividend Equivalents shall not be deemed to be “Covered Compensation” under any other benefit plan of the Corporation. 
 15. Adjustments. 
 The Performance-Based RSUs and the Shares underlying the
Performance-Based RSUs shall be subject to adjustment and conversion pursuant to the terms of Section 7.1 of the Plan. 

16. Tax Withholding. 
 Any payment or delivery of Shares pursuant to this Agreement shall be subject to the Corporation’s rights to withhold applicable Federal, state, local and non-United States taxes in accordance with
Section 8.5 of the Plan. 
 17. Section 409A. 

The provisions of this Agreement shall be construed and interpreted to comply with Section 409A of the Code so as to avoid the
imposition of any penalties, taxes or interest thereunder. 
 18. Clawback. 

The Performance-Based RSUs are subject to the terms of the Corporation’s recoupment, clawback or similar policy as it may be in
effect from time to time, as well as any similar provisions of applicable law, any of which could in certain circumstances require repayment or forfeiture of the Performance-Based RSUs or any Shares or other cash or property received with respect to
the Performance-Based RSUs (including any value received from a disposition of the Shares acquired upon payment of the Performance-Based RSUs). 

  
 - 7 -

 
	
	CORELOGIC, INC.
	
	By:                             
                                         
                          
	      Name: [Anand Nallathambi]
	      Title: [Chief Executive Officer]
	
	Date: [Grant Date]

 Acknowledged and agreed as
of the Date of Grant: 
  

			
	Printed Name:	  	[Participant Name]
		
	Date:	  	[Acceptance Date]

 [NOTE: GRANT WILL BE ACCEPTED
ELECTRONICALLY] 

  
 - 8 -

 APPENDIX A 
 Certain Definitions 
 “Affiliate” means any entity other than the
Corporation and any Subsidiary that is affiliated with the Corporation through stock or equity ownership or otherwise and is designated as an Affiliate for purposes of the Plan by the Administrator. 

“Cause” has the same meaning as in the Participant’s employment agreement with the Corporation, a Subsidiary or an Affiliate (if
any) as in effect at the time of the Participant’s Termination, or if the Participant is not a party to such an employment agreement (or is not a party to such an employment agreement that contains a definition of “cause”),
“Cause” means: (i) embezzlement, theft or misappropriation by the Participant of any property of any of the Corporation or its Affiliates; (ii) the Participant’s breach of any fiduciary duty to the Corporation or its
Affiliates; (iii) the Participant’s failure or refusal to comply with laws or regulations applicable to the Corporation or its Affiliates and their businesses or the policies of the Corporation and its Affiliates governing the conduct of
its employees or directors; (iv) the Participant’s gross incompetence in the performance of the Participant’s job duties; (v) commission by the Participant of a felony or of any crime involving moral turpitude, fraud or
misrepresentation; (vi) the failure of the Participant to perform duties consistent with a commercially reasonable standard of care; (vii) the Participant’s failure or refusal to perform the Participant’s job duties or to perform
specific directives of the Participant’s supervisor or designee, or the senior officers or Board of Directors of the Corporation; or (viii) any gross negligence or willful misconduct of the Participant resulting in loss to the Corporation
or its Affiliates, or damage to the reputation of the Corporation or its Affiliates. 
 “Change in Control” means the happening
of any of the following after the date hereof: 
  

	 	(a)	The consummation of a merger or consolidation of the Corporation with or into another entity or any other corporate reorganization, if fifty percent (50%) or more
of the combined voting power of the continuing or surviving entity’s securities outstanding immediately after such merger, consolidation, or other reorganization is owned by persons who were not shareholders of the Corporation immediately prior
to such merger, consolidation, or other reorganization. 

  

	 	(b)	The sale, transfer, or other disposition of all or substantially all of the Corporation’s assets or the complete liquidation or dissolution of the Corporation.

  

	 	(c)	A change in the composition of the Board occurring within a two (2) year period, as a result of which fewer than a majority of the directors are Incumbent
Directors. “Incumbent Directors” shall mean directors who are directors of the Corporation immediately following the consummation of the transactions contemplated by the Separation and Distribution Agreement by and between the
Corporation and the First American Financial Corporation dated June 1, 2010 (the “Separation Agreement”). “Incumbent Directors” shall also include directors who are elected, or nominated for election, to the
Board with the affirmative votes of at least a majority of the Incumbent Directors at the time of such election or nomination, but shall not include an individual not otherwise an Incumbent Director whose election or nomination is in connection with
an actual or threatened proxy contest relating to the election of directors to the Corporation. 

  

	 	(d)	 Any transaction as a result of which any person or group is or becomes the “beneficial owner” (as defined in Rule 13d-3 under the
Securities Exchange Act of 1934), directly or indirectly, of securities of the Corporation representing at least thirty percent (30%) of the total voting power of the Corporation’s then outstanding voting securities. For purposes of this
paragraph, the term “person” shall have the same meaning as when used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, but shall exclude: (i) a trustee or other fiduciary holding securities under an employee
benefit plan of the Corporation or of a Subsidiary of the Corporation; (ii) so long as a person does not thereafter increase such person’s beneficial ownership of the total voting power represented by the Corporation’s then
outstanding voting securities, a person whose beneficial ownership of the total voting power represented by the 

  
 - 9 -

	 	 
Corporation’s then outstanding voting securities increases to thirty percent (30%) or more as a result of the acquisition of voting securities of the Corporation by the Corporation
which reduces the number of such voting securities then outstanding; or (iii) so long as a person does not thereafter increase such person’s beneficial ownership of the total voting power represented by the Corporation’s then
outstanding voting securities, a person that acquires directly from the Corporation securities of the Corporation representing at least thirty percent (30%) of the total voting power represented by the Corporation’s then outstanding voting
securities. 

 A transaction shall not constitute a Change in Control if its sole purpose is to change the
state of the Corporation’s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Corporation’s securities immediately before such transaction. 

For the avoidance of doubt, the consummation of any or all of the transactions in the Separation Agreement is not considered a Change in
Control for purposes of this Agreement. 
 “Disability” means the inability to engage in any substantial gainful occupation to
which the relevant individual is suited by education, training or experience, by reason of any medically determinable physical or mental impairment, which condition can be expected to result in death or continues for a continuous period of not less
than twelve (12) months. 
 “Termination” means the time when the Participant ceases the performance of services for the
Corporation, any Affiliate or Subsidiary, as applicable, for any reason, with or without Cause, including a Termination by resignation, discharge, retirement, death or Disability, but excluding (a) a Termination where there is a simultaneous
reemployment or continuing employment of the Participant by the Corporation, any Affiliate or Subsidiary, (b) at the discretion of the Administrator, a Termination that results in a temporary severance, and (c) at the discretion of the
Administrator, a Termination of an employee of the Corporation that is immediately followed by the Participant’s service as a non-employee director of the Board. Notwithstanding any other provisions of the Plan or this Agreement to the
contrary, a Termination shall not be deemed to have occurred for purposes of any provision the Plan or this Agreement providing for payment or distribution with respect to an award constituting deferred compensation subject to Code Section 409A
upon or following a termination of employment or services unless such termination is also a “separation from service” within the meaning of Section 409A of the Code. 

  
 - 10 -Amended and Restated Prime Vendor Agreement

 Exhibit 10.40 
 [*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION. 

AMENDED AND RESTATED PRIME VENDOR AGREEMENT 
 FOR LONG-TERM CARE PHARMACIES 
 This Amended and Restated Prime Vendor
Agreement for Long-Term Care Pharmacies (“Agreement”) is made as of January 1, 2011 (“Effective Date”) by and between AmerisourceBergen Drug Corporation, a Delaware corporation (“ABDC”), on the
one hand, and PharMerica Corporation (“PMC”), a Delaware corporation; Pharmacy Corporation of America (“PCA”), a Delaware corporation; and Chem Rx Pharmacy Services, LLC, a Delaware limited liability company
(“Chem Rx”), on the other. (Collectively, PMC, PCA and Chem Rx are sometimes referred to hereafter as “Customer”.) 
  

	 	A.	ABDC is a national distributor of Products and Services. 

  

	 	B.	As of the Effective Date, Customer owns, operates and manages approximately 100 LTCPs. 

 

	 	C.	ABDC and PMC are parties to that certain Prime Vendor Agreement dated August 1, 2007 (“Prior PVA”). 

 

	 	D.	ABDC and Chem Rx are parties to that certain Prime Vendor Agreement (“Chem Rx PVA”) dated May 1, 2007, as assigned to and assumed by Chem Rx on or
about November 4, 2010 by Chem Rx Corporation et al, pursuant to approval by the United States Bankruptcy Court for the District of Delaware (Case Number 10-11567). 

 

	 	E.	The parties intend by this Agreement to amend and restate the Prior PVA, to terminate the Chem Rx PVA and to set forth their obligations to each other for the Program.

 NOW THEREFORE, the parties agree as follows: 

 

	1.	RECITALS & DEFINITIONS; PRICING AND PAYMENT TERMS 

 A. The foregoing recitals are incorporated herein as an integral part of this Agreement. Capitalized terms used herein that are not defined in the body of this Agreement shall have the meaning ascribed to
them on Exhibit “5” (“Definitions”). 
 B. ABDC shall be the Primary Vendor of all requirements of
Customer’s Facilities for Products, including that Customer purchases no less than 98% of all Branded Rx from ABDC. Customer will pay, within terms, Product costs and Program fees pursuant to payment terms in Exhibit “1”
(“Pricing/Payment Terms”). Customer’s compliance with the Primary Vendor requirements encompassed by the definition of that term in Exhibit 5 as incorporated herein will be verified * by ABDC and must be * as provided in
Section 10(A). Notwithstanding the Primary Vendor requirements, Customer may purchase directly from a manufacturer if, due to a product shortage or allocation, the manufacturer requires that Customer do so. ABDC agrees that, in accordance with
the definition of Facility in Exhibit 5, the Primary Vendor * will not apply to Customer’s newly acquired pharmacies with existing agreements with other distributors until such time as such newly acquired pharmacies become Facilities hereunder.
By way of example, Table 1 of Exhibit 7 illustrates how the parties will * Customer’s * with the Primary Vendor requirements. 
 C. Orders for Products will be electronically transmitted (CSOS for Schedule II controlled substances) and will describe Products that ABDC will provide to Customer, the quantity and designated delivery
location. Other than supplier back-ordered Products, ABDC will make * to deliver orders placed by ABDC’s normal order cut-off time by the next delivery day. All payment plans must be by electronic funds transfer (“EFT”). The * in the
Pricing/Payment Terms, terms, and conditions under this Agreement, including participation in the PRxO Generics Purchase Program, * with ABDC as of the date hereof. A * is a third-party * with *, taking into consideration *, including *. 

  

					
	PMC – ABDC Amended and Restated PVA January 1, 2011	 	1	 	

	2.	PRxO GENERICS PURCHASE PROGRAM 

 A. Customer must participate in the PRxO Generics Purchase Program as provided in this Agreement and pursuant to standard PRxO Generics Purchase Program requirements as amended from time to time by ABDC.
Customer acknowledges and agrees that it will be able to benefit by having ABDC administer the PRxO Generics Purchase Program for a * Outsourcing Fee, as specified in Paragraph 2(C) of the Pricing/Payment Terms. 

B. By agreeing to participate in the PRxO Generics Purchase Program, Customer must purchase from ABDC and through the PRxO Generics
Purchase Program no less than 95% of its non-Injectable Generic Rx, as verified * by ABDC and * as provided in Section 10(A). With respect to each Generic Rx purchased by Customer under the PRxO Generics Purchase Program, ABDC shall use its *
to provide Customer * prior to changing suppliers of such Products. Any changes by ABDC in its PRxO Generics Purchase Program will be non-discriminatory, generally applicable to ABDC’s customers and consistent with the terms of this Agreement.
Table 1 of Exhibit 7 establishes how the parties will * Customer’s Generic Rx * requirements. 
  

	3.	SPECIALTY DISTRIBUTIONS AND * 

 ABDC will provide to Customer its * of * that are in * due to, for example, manufacturer shortages or unanticipated demand, including any specialty Products or other Products with limited distribution or
supply. ABDC makes such * based upon each *. Upon request, ABDC will attempt to acquire short-supply Products and, upon their purchase by Customer, such inventory would be * for Customer and would not *. Additionally, upon request, ABDC can order
short-supply Products, which Products can be “shipped upon arrival” to Customer’s Facilities. 
  

	4.	CUSTOMER LOCATIONS & DELIVERIES 

 ABDC will deliver Products to each Facility five days a week (Monday – Friday, or as otherwise agreed to from time to time by Customer and ABDC), once a day except holidays and warehouse physical
inventory days. ABDC will provide * at its distribution centers * hours a day, * days a week, for which ABDC will provide Customer with emergency contact information for after-hours access. Additionally, Customer will be entitled to * per * at *.
Customer will be charged $* for * to the Facility. Customer may receive * per * per * (as long as it is * ABDC’s distribution center during hours such distribution center is staffed) at *. ABDC will use * to meet a requested delivery time for
emergency orders. If ABDC cannot do so, Customer may fill Emergency Orders outside the Program on such occasions using another provider and such * shall be * as so specified in Exhibit 7 for purposes of Customer’s Generic Rx *. Service to
Facilities in Alaska, Hawaii and U.S. territories may be subject to a delivery surcharge. 
  

	5.	RETURNED GOODS POLICY 

Customer will only return Products to ABDC in accordance with ABDC’s * policy for return Products, a copy of which is attached as
Exhibit 4 (“Returns Policy”). If Customer returns more than *% of its OTC Net Purchases, or *% of its pharmaceutical Net Purchases in any month, Customer may be assessed an additional restocking fee over any standard stocking fee in
the Returns Policy. Customer will return only Product purchased from ABDC for which Customer has submitted the invoice number and date of purchase. ABDC may reject returns not accompanied by the invoice number and date of purchase or that exceed in
amount either the *% return limit or the amount on the referenced invoice number. ABDC reserves the right to refuse all future returns from Customer in the event that Customer submits any counterfeit Product for return. The calculation of Customer
returns, Customer OTC Net Purchases, and all other calculations under this Agreement related to the volume of Customer’s purchases of Products will be based on * and not the *. 

  

					
	PMC – ABDC Amended and Restated PVA January 1, 2011	 	2	 	

	6.	ADDITIONAL SERVICES & PROVISIONS 

 A. Services are listed in Exhibit “2”. Terms, conditions and other provisions are set forth in Exhibit “3” (“Provisions”). 

B. ABDC may, from time to time, develop policies and procedures relative to new or existing Services offered to customers, on an interim
or as-needed basis. If ABDC develops such policies or procedures or changes current ones, ABDC will notify Customer in writing at least thirty (30) days before such changes are effective. Any changes by ABDC that apply to Customer from time to
time under this Agreement, including its exhibits, must be non-discriminatory, generally applicable to ABDC’s customers, and consistent with the terms of this Agreement. 

 

	7.	TERM OF AGREEMENT 

 A. The
parties intend by this Agreement to (i) amend and restate the Prior PVA and (ii) terminate the Chem Rx PVA, such that all obligations thereunder are and will be governed by this Agreement as of the Effective Date, subject to the following
sentence. Except as otherwise agreed, rights and obligations of the parties under the Prior PVA and Chem Rx PVA that accrued prior to the Effective Date will survive and each party shall satisfy all such obligations imposed on it thereunder
according to the terms of each of the Prior PVA and Chem Rx PVA. 
 B. Subject to termination of this Agreement pursuant to
Paragraph 5 of the Provisions, the term will be from the Effective Date until September 30, 2013 (“Term”). Unless either party provides notice of termination at least 90 days (but not more than 120 days) prior to the expiration
of the Term, this Agreement will automatically renew for additional * periods, subject to termination pursuant to Paragraph 5 of Exhibit 3 (Provisions). 
  

	8.	RECORDS 

 To the extent
required by 42 U.S.C. §1395x(v)(1), until four (4) years after termination of this Agreement, ABDC will make available upon written request to the Secretary of the U.S. Department of Health & Human Services, the Comptroller
General, or their authorized representatives, a copy of this Agreement and all records required to certify the nature and extent of costs of Products and Services provided by ABDC under this Agreement. ABDC will ensure, to the extent it carries out
its duties through a subcontract with a value or cost of $10,000 or more in a twelve (12) month period with a related organization, such subcontract will contain similar provisions. Notwithstanding the foregoing, ABDC will have no obligation to
make public documents subject to attorney-client privilege. 
  

	9.	NOTICES 

 Notices must be
in writing and sent certified mail, prepaid, return receipt requested, or sent by facsimile to the address or facsimile number below. Parties may change this information by written notice to the other party. Pursuant to the Telephone Consumer
Protection Act of 1991, 47 U.S.C. §227, Customer consents to receiving notices, including product updates, recalls, new product launches and programs, advertisements and other marketing materials by telephone facsimile (“fax”) machine
from ABDC, its affiliates and their related companies, to the fax number set forth below. 
  

			
	To Customer:	  	PharMerica Corporation
		  	1901 Campus Place
		  	Louisville, KY 40299
		  	Attn: Chief Financial Officer
		  	CC: General Counsel
		  	Fax: (502) 261-2375

  

					
	PMC – ABDC Amended and Restated PVA January 1, 2011	 	3	 	

			
		
	with a copy to:	  	Holland & Knight LLP
		  	10 St. James Avenue, 11th Floor
		  	Boston, MA 02116
		  	Attn: Jeffrey W. Mittleman, Esq.
		  	Fax: (617) 523-6850
		
	To ABDC:	  	AmerisourceBergen Drug Corporation
		  	1300 Morris Drive
		  	Chesterbrook, PA 19087-5594
		  	Attn: Senior Vice President, Alternate Care
		  	Fax: 610-727-3601
		
	with a copy to:	  	AmerisourceBergen Corporation
		  	1300 Morris Drive
		  	Chesterbrook, Pennsylvania 19087-5594
		  	Attn: General Counsel
		  	Fax: (610) 727-3612

  

	10.	COMPLIANCE CERTIFICATION 

A. No later than thirty (30) days after the end of each calendar year during the Term, Customer shall provide ABDC with a written
certification, executed by a duly authorized officer of PMC, attesting to Customer’s compliance during the preceding year or partial year with (i) the Primary Vendor requirements as provided in Section 1(B) above, and (ii) the
95% sourcing requirement with respect to the PRxO Generics Purchase Program as provided in Section 2(B) above. A form of Customer’s compliance certificate is attached as Exhibit 6. 

B. No later than thirty (30) days after the end of each calendar year during the Term, ABDC shall provide Customer with a written
certification, executed by a duly authorized officer, attesting to Customer’s receipt of Customer’s * of * as provided in Paragraph 2(B) of Pricing/Payment Terms. A form of ABDC’s compliance certificate is attached as Exhibit 6.

  

	11.	EXHIBITS 

 The following
exhibits to this Agreement are incorporated by this reference. 
  

	 	1	Pricing/Payment Terms 

  

	 	2	* Services 

  

	 	3	Provisions 

  

	 	4	Returns Policy 

  

	 	5	Definitions 

  

	 	6	Forms of Compliance Certificates 

  

	 	7	* Generic Rx Purchases and * Calculations 

  

					
	PMC – ABDC Amended and Restated PVA January 1, 2011	 	4	 	

 IN WITNESS WHEREOF, the parties have had a duly authorized officer, partner or principal
execute this Amended and Restated Prime Vendor Agreement as of the Effective Date. 
  

									
	CUSTOMER:	 		 	ABDC:
	PharMerica Corporation	 		 	AmerisourceBergen Drug Corporation
					
	By:	 	 /s/ Robert McKay
	 		 	By:	 	 /s/ Robert Mauch

	Name:	 	Robert McKay	 		 	Name:	 	Robert Mauch
	Title:	 	SVP	 		 	Title:	 	Senior Vice President, Alternate Care
				
	Chem Rx Pharmacy Services, LLC	 		 		 	
					
	By:	 	 /s/ Robert McKay
	 		 		 	
	Name:	 	Robert McKay	 		 		 	
	Title:	 	SVP	 		 		 	
				
	Pharmacy Corporation of America	 		 		 	
					
	By:	 	 /s/ Robert McKay
	 		 		 	
	Name:	 	Robert McKay	 		 		 	
	Title:	 	SVP	 		 		 	
				
	 Agreed and acknowledged with respect to
 termination of the Chem Rx PVA:
	 		 		 	
				
	 Chem Rx Pharmacy Services, LLC, as assignee of
 BJK, Inc.; ChemRx New Jersey, LLC; and
 ChemRx/Salerno’s, LLC
	 		 		 	
					
	By:	 	 /s/ Robert McKay
	 		 		 	
	Name:	 	Robert McKay	 		 		 	
	Title:	 	SVP	 		 		 	

  

					
	PMC – ABDC Amended and Restated PVA January 1, 2011	 	5	 	

 EXHIBIT 1 TO 
 PRIME VENDOR AGREEMENT 
 PRICING / PAYMENT TERMS 

In addition to payment for Products, Customer will pay ABDC the following Program and other fees for ABDC’s Product distribution and Services for
Customer and its Facilities. Pricing does not reflect any * or * to a *. If Customer contracts with a GPO, Customer will pay any such fees to the applicable GPO (or any increase in such fees) during the Term. In any event, ABDC will not pay a GPO
fee unless and until a group designation form signed by Customer is filed with ABDC. 
  

	1.	PROGRAM FEES 

 A. Price
of Goods. 
 (i) Customer will pay the following Price of Goods, based upon the definition of Cost in Exhibit 5, for
Products other than (a) ABDC Special Price Products (as provided in Paragraph 1(A)(ii) below), and (b) Generic Rx purchased under the PRxO Generics Purchase Program (as provided in Paragraph 1(A)(iii) below). ABDC will add to the billed
amount any applicable sales, use, business and occupation, gross receipts or other tax. Price of Goods may be adjusted based upon *of * of * as provided in Paragraph 2(D) below over the *. 

 

			
	 Purchases of
Products

	 Requirement/Category
	  	 Price of Goods

		
	To receive this pricing, Customer must purchase no less than 98% of total Branded Rx purchases from ABDC and at least 95% of Generic Rx purchases through the PRxO Generics Purchase
Program	  	*%*
		
	 DEA Class II Controlled Substances
 Ordered via CSOS
	  	*%
		
	 DEA Class II Controlled Substances
 Not Ordered via CSOS
	  	*% if *% of the Facilities are * via *, measured * and including those Facilities or pharmacists with *.

 

	*	For Branded Rx shipped to a Facility in Hawaii, the applicable * will be * basis points * (e.g., *%). For Brand Rx that is drop shipped to Customer * from * but *, the
applicable Price of Goods will be *%. 

 (ii) ABDC Special Price Products will not be billed based upon *, but
will instead be billed in accordance with the * from time to time for such Products and Services (and, as applicable to Customer, will be * to ABDC’s customers, and consistent with the terms of this Agreement). Purchases of ABDC Special Price
Products count when determining purchase volumes for “Primary Vendor” status. ABDC will provide * notice to Customer for a Price of Goods change for ABDC Special Price Products due to * % or *. 

(iii) PRxO Generics purchased under the PRxO Generics Purchase Program will be billed in accordance with Paragraph 2 of this Exhibit 1.

 B. Purchase Rebate. Within thirty days after the Effective Date, and thereafter within thirty days after each annual
anniversary of the Effective Date during the Term, Customer will receive a rebate (“Purchase Rebate”) in the amount of * dollars ($*), representing a * % * off the Price of Goods for the *dollars ($*) in * during the * of the Agreement. In
the event Customer does not make * $* in any such *, Customer agrees to * to ABDC * of the Purchase Rebate *. The Purchase Rebate will be payable * Customer. Customer must comply fully with all terms of this Agreement to be eligible for the
Purchase Rebate. 

  

					
	PMC – ABDC Amended and Restated PVA January 1, 2011	 	6	 	
	 Customer will delete this Exhibit “1” (or request confidential
treatment)
 if it discloses this Agreement for any reason, including in any SEC filing

 C. Additional * Services. The additional * Services in Exhibit “2”
will be provided to Customer’s Facilities, at the election of Customer’s Facilities, by ABDC for * if Customer * ABDC as *. In the event Customer does not * ABDC as *, such Services will be provided at a *. 

D. Small Order Charge. If Customer purchases less than $* per * per *, a delivery charge of $* per delivery will be assessed for
each order that is less than $*. ABDC may adjust the per-delivery charge from time to time to reflect ABDC’s actual shipping and handling costs. 
 E. Contract Administration. In administering Customer’s supplier contracts, including those established by Customer on its own or those established by a GPO under which Customer participates,
Customer must (i) provide a copy of new contracts, (ii) comply with supplier’s terms, (iii) use all products for its “own use” (as defined in judicial and legislative interpretations), (iv) notify ABDC at least *
days before it changes suppliers, and (v) upon changing suppliers, assist ABDC in disposing of any excess inventory acquired for Customer. Additionally, Customer will notify ABDC before discontinuing purchases of any special inventory that it
has requested that ABDC stock (whether or not pursuant to a contract) and assist ABDC in disposing of any excess of such inventory. Promptly after receiving notice of the denial of, or failure to pay, GPO or manufacturer/supplier chargebacks, ABDC
shall provide Customer written notice of any unpaid chargebacks, and when invoiced, Customer will promptly reimburse ABDC for any unpaid chargebacks that are (x) denied by a GPO or manufacturer/supplier or (y) not paid within * days and,
in either case, Customer will look solely to such GPO or manufacturer/supplier for redress; provided that the unpaid chargeback is processed through ABDC’s standard credit and rebill procedures. 

 

	2.	PRxO GENERICS PURCHASE PROGRAM 

 A. Administration Services. ABDC will have full responsibility for administering the PRxO Generics Purchase Program, including supplier selection, Product selection, Product price negotiation,
contract administration, purchasing, automated compliance assurance, contract management and reporting. Under the PRxO Generics Purchase Program, ABDC will invoice Customer at the * under ABDC’s *, * pricing to Customer, plus *. ABDC will issue
to Customer a * for the * between the * to Customer when Product is * (i.e. including any * to the *) and the * plus the * and provide * for such audit, with * issued within * days of the end of each *. 

B. PRxO Rebates. ABDC will * to Customer its * of PRxO Rebates as determined by comparing Customer’s * of * as a * of * by *
ABDC *. ABDC’s compliance with its obligations under this Paragraph 2(B) must be certified to by an officer of ABDC as provided in Section 10(B). 
 C. Outsourcing Fee. ABDC will provide such PRxO Generics Purchase Program services for an * equal to *% of ABDC’s *. 
 D. Price of Goods Adjustment. 
 (1) If Customer does not meet the 95% PRxO
Generic Rx purchasing requirements under the PRxO Generics Purchase Program set forth in Section 2B of this Agreement for the immediately prior quarter, then ABDC may increase Customer’s Price of Goods (Branded Rx and other Products) in
the current quarter by *% (*) for each *% that Customer’s total * for the immediately prior quarter were below the minimum * requirement of 95.00% for such quarter (calculated pursuant to the foregoing formula). By way of example, if
Customer’s * under the above formula were 93.00% for a quarter, the effective Price of Goods for Branded Rx for the following quarter would change (by *%) from *% to *%. 
 (2) If Customer does not meet the *% CSOS requirement set forth in the Price of Goods table, measured quarterly, then the Cost for Class II Controlled Substances not ordered via CSOS will * to *%.

 E.* Expectancy. ABDC acknowledges Customer’s expectancy as of the Effective Date that Customer’s participation in the PRxO
Generics Purchase Program hereunder will result in * of approximately *% based on Customer’s aggregate Generic Rx purchases under the PRxO Generics Purchase Program as provided herein during each Contract Year * that Customer * for the *
Generic Rx purchases if the pricing structure provided for in the * had been * for the * at the *. 
  

	 	i.	The parties agree to track and measure the projected annual performance within * days of the * of each *, review performance and discuss expected results for the next
quarter. 

  

					
	PMC – ABDC Amended and Restated PVA January 1, 2011	 	7	 	
	 Customer will delete this Exhibit “1” (or request confidential
treatment)
 if it discloses this Agreement for any reason, including in any SEC filing

	 	ii.	Within * days of the end of each Contract Year (or January of the subsequent calendar year if the last Contract Year is not twelve months), ABDC will calculate
Customer’s actual performance and * for the *, or pro rata performance and * if the Contract Year is less than twelve months. If the * is *% (“Shortfall”) for any Contract Year, ABDC agrees to * Customer the * between the * and
the * that Customer * if a *% * had been achieved. ABDC will remit such * within * days of the annual measurement. 

  

	 	iii.	If the annual performance *% (“Excess”) for any Contract Year, ABDC will *% of *, in addition to the Outsourcing Fee. ABDC will be permitted to *
against the * to Customer. 

  

	 	iv.	If the annual performance is *%, either party may terminate the Agreement in accordance with Section 5.1 (c) of Exhibit 3. 

 

	 	v.	The Shortfall will be determined by * a *% *amount using Customer’s *and subtracting the * from this amount. The Excess will be determined by * a *% * amount using
Customer’s * and subtracting the * for the *% amount. 

 The following chart establishes if and when
Shortfall and Excess adjustments apply: 
  

					
	 Actual Annual Savings Performance
	  	Performance
Shortfall Applies	  	Performance Excess *
Applies
	 *% or Greater
	  	No	  	Yes
	 Between *% and *%
	  	No	  	No
	 *% or less
	  	Yes	  	No
	 *% or less
	  	Termination right

 The following chart establishes the formula to be used in calculating Excess and Shortfall: 
  

					
		  	* PRxO Generic Rx purchases at *% *minus the *	  	
			
	* minus	  	----------------------- divided by -----------------------	  	Multiplied by *%
			
		  	* PRxO Generic Rx purchases at *% *	  	

  

	3.	PAYMENT TERMS 

 A.
Weekly Payment. Customer agrees to weekly payment terms pursuant to which payment for invoices for purchases made Saturday through Friday must be received on or before the following Friday. 

B. Terms. All payments must be received for deposit to ABDC’s account by the due date by EFT. 

 

	4.	SERVICE LEVELS 

 For
pharmaceutical Products, ABDC will meet an adjusted fill rate service level of *% each calendar month. The fill rate is the ratio between lines shipped and lines ordered (total lines not filled (adjusted as follows), divided by total lines ordered).
The fill rate will be adjusted to reflect unavailable Product (manufacturer’s backorders or other unavailability without fault by ABDC, including common carrier delays), partial ships (*% or *), repeat orders within * hours, Products not
ordered by Customer during the prior * days or Customer’s per-week usage exceeds its per-week estimates by more than *%, and Force Majeure events (as defined in Provisions Paragraph 9.1). ABDC’s computerized reports will be used to
determine the actual level achieved. Customer will provide its best usage estimates on Products at least * days prior to its first order of a Product (both new Products and Products that have not been ordered during the prior * days) so that ABDC
can maintain its service level commitment. Products must be purchased once per month to remain on the list of Products for which the service level commitment applies. Any Product not ordered in a given month can be reinstated on such list when
Customer notifies ABDC it is resuming the ordering of such Product on a monthly 

  

					
	PMC – ABDC Amended and Restated PVA January 1, 2011	 	8	 	
	 Customer will delete this Exhibit “1” (or request confidential
treatment)
 if it discloses this Agreement for any reason, including in any SEC filing

 
basis. ABDC may offer a substitute for any Product that is not available for delivery, and if the substitute Product is accepted by the Customer, in the Customer’s reasonable discretion, the
order will be deemed filled. If ABDC’s adjusted service level for all Facilities does not meet such threshold, ABDC will pay to each Facility for which the service level was not met a service level penalty as follows, which amount will be paid
as a credit by the * of the * and which payment will be Customer’s sole remedy for any failure to meet the fill rate. 
  

			
	*% to *%	  	* (*%) of *such Facility during such month.
	*% to *%	  	* (*%) of *such Facility during such month.
	Less than *%	  	* (*%) of * by such Facility during such month.

  

					
	PMC – ABDC Amended and Restated PVA January 1, 2011	 	9	 	
	 Customer will delete this Exhibit “1” (or request confidential
treatment)
 if it discloses this Agreement for any reason, including in any SEC filing

 EXHIBIT 2 TO 
 AMENDED AND RESTATED PRIME VENDOR AGREEMENT 
 ADDITIONAL * SERVICES

 1. Services. The following Services are offered to Customer by ABDC for the * in Paragraph 1(B) of Pricing/Payment Terms.
At its discretion, Customer may elect which of these Services to utilize. 
  

	 	•	 	 * 

  

	 	•	 	 * 

  

	 	•	 	 * 

  

	 	•	 	 * 

 ABDC may * any Services
as it deems appropriate, in which case ABDC will make a * in the * based upon the * of the * Services. In addition, from time to time ABDC may * Services, at such * as *. Any such * by ABDC that apply to Customer will be * to ABDC’s customers,
and consistent with the terms of this Agreement. 
 2. Ordering & Reporting Software and Hardware 

 

	 	•	 	 * for *. 

  

	 	•	 	 * for * for Facilities with * $*per * (or, for Facilities purchasing * $* per *, one * at *. 

 

	 	•	 	 * for a * of $* per * and * and * for $* per * per *. 

 

	 	•	 	 *. 

 ABDC retains title to
all ordering and reporting hardware and software and, pursuant to Provisions Paragraph 5.3. Customer must return them upon termination of this Agreement. 
  

	*	and related services will be offered at *. 

3. Recalls 
 ABDC will notify Customer
of all recalls as instructed in the supplier’s notification. 
 4. Drop Ship Service 

ABDC provides drop ship service when Customer’s needs dictate this approach and the supplier meets ABDC’s liability insurance and other
requirements. Drop shipments may be subject to an additional charge. 

  

					
	PMC – ABDC Amended and Restated PVA 1/1/2011	 	10	 	

 EXHIBIT 3 TO 
 AMENDED AND RESTATED PRIME VENDOR AGREEMENT 
 PROVISIONS

 

 1. RECORDS, AUDITS. 
 ABDC will maintain records of transactions during the Term and for one year after. Customer’s employees may audit such records only pursuant to ABDC’s audit policies, as modified from time to
time. Such audits may be conducted only during ordinary business hours and upon reasonable notice and may only cover * days prior to the request or any shorter period set by the manufacturer for chargeback audits. No audit may cover any period
previously audited. All costs of such audit will be borne by Customer, including costs to produce records. If an audit shows net overcharges or undercharges and ABDC agrees with such findings, (i) ABDC will credit or charge Customer within *
days of receipt of written notice of the net overcharge (or, if later, within * days of receiving an applicable supplier’s credit) or undercharge and (ii) ABDC will * of any audit *, including *, not *. If there is a net overcharge,
Customer may expand the audit to * days prior to the request. 
 2. DUTIES OF CUSTOMER 

2.1 Primary Vendor Orders. For Products required by Facilities, Customer will submit an electronic order for all Products. If allowed,
non-electronic orders may be subject to additional charges. 
 2.2 Disclosure. Each party will comply with all laws, including reporting
or reflecting discounts, rebates and other price reductions pursuant to 42 U.S.C. §1320a-7b(b)(3)(A) on cost reports or claims submitted to federal or state healthcare programs, retaining invoices and related pricing documentation and making
them available on request to healthcare program representatives. 
 2.3 Notice of Changes. Customer and each Facility will promptly
notify ABDC of changes in ownership, Change-in-Control, name, business form (e.g., sole proprietorship, partnership or corporation) or state of incorporation or formation. 
 2.4 No Set-Off. Customer’s obligation to pay for Products will be absolute, unconditional and not subject to reduction, set-off, counterclaim or delay. 

2.5 Billing Statements. Billing disputes must be brought promptly to the attention of ABDC’s accounts receivable department and any claim
against ABDC will be barred unless commenced within twelve (12) months after receipt of the first statement containing the amount in dispute or Customer will be deemed to accept the accuracy of such statements and to waive its right to dispute
the amount. 
 2.6 Late Payment. All payments must be received in ABDC’s account during normal business hours on or before the date
due. Drivers and other ABDC employees cannot accept cash. Price of Goods reflects a prompt payment discount. If payment is not received by the due date, ABDC will invoice Customer such unearned discount by recalculating Price of Goods, solely with
respect to the Products for which payment was not received or late, based on Cost *% (or, if greater, *% more than the invoiced Price of Goods) effective as of the due date. Thereafter, if payment is delinquent, ABDC may withhold any payments to
Customer and will assess a per-day late payment fee of the lower of *% (*%/360) or the maximum rate permitted by law on the outstanding balance until paid, beginning on the first (1st) business day after such due date. Additionally, ABDC may
adjust * solely to reflect such unearned discount or late payment fees; provided, however, ABDC will * any such adjustment following Customer’s account being current for *. Such rights are in addition to ABDC’s other remedies and will not
relieve Customer of its obligation to make prompt payment in accordance with this Agreement. 
 2.7 Title And Risk Of Loss. All goods are
F.O.B. Customer’s location, with freight prepaid for normal delivery. Expedited delivery is extra. Title and risk of loss pass upon delivery to Customer. 
 2.8 Extension Of Credit. Payment terms are an extension of credit based upon an evaluation of Customer’s financial condition upon commencement of this Agreement as reflected in written
information from Customer. Customer and each Account will abide by ABDC’s standard credit terms as amended from time

 
to time by ABDC. Customer will promptly notify ABDC in writing of any Claim that, with an unfavorable result, would have a material adverse effect on Customer’s financial condition or
operation. Upon request, Customer will furnish ABDC complete annual and quarterly financial statements and other evidence of its financial condition necessary to establish, in ABDC’s opinion, Customer and each Account’s ability to perform
its obligations. If ABDC reasonably believes Customer or any Account’s ability to make payments may be materially impaired, ABDC may from time to time amend Customer’s payment terms, require past due amounts to be paid and/or require
posting of adequate security or such other documents as ABDC may require. Pending receipt of requested items, ABDC may withhold delivery of Products and providing Services; place Customer on a C.O.D. basis if ABDC has not received payment when due
after giving notice by 10:00 a.m. and giving Customer until 2:00 p.m. the same day for ABDC to receive payment; and/or require Customer to pay part or all of any past due amount as a condition to continued service. 

3. NO WARRANTIES 
 Customer acknowledges
that ABDC is not the manufacturer of any Products and ABDC DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING THOSE OF MERCHANTABILITY, NON-INFRINGEMENT AND FITNESS FOR A PARTICULAR PURPOSE, FOR PRODUCTS AND SERVICES. No oral or written
information provided by ABDC, its employees or other representatives will create any such warranty. In no event will ABDC be liable for any special, incidental or consequential damages in connection with or related to Products, hardware, Software,
including ordering software, or Services. 
 4. CONFIDENTIALITY 
 Each party and its employees or representatives (“Receiving Party”) will protect all proprietary and confidential information (“Confidential Information”) disclosed by the other
(“Disclosing Party”) and not use or disclose it except in connection with the Program or as otherwise agreed. Confidential Information does not include information (i) available on a non-confidential basis, (ii) known or able to
be formulated by Receiving Party, or (iii) required to be disclosed by law. Pricing and payment terms are confidential and may not be shared with any third party. Customer will remove Exhibit “1” and Exhibit 7 if it discloses
this Agreement for any reason, including in the course of any due diligence, and Customer will request confidential treatment in a Securities and Exchange Commission filing. 
 5. TERMINATION OF AGREEMENT 
 5.1 Default. In addition to other available remedies,
either party may immediately terminate this Agreement “for cause” upon written notice to the other party upon the other party’s: 

(a) (i) Filing an application for or consenting to appointment of a trustee, receiver or custodian of its assets; (ii) having an order for relief
entered in Bankruptcy Code proceedings; (iii) making a general assignment for the benefit of creditors; (iv) having a trustee, receiver or custodian of its assets appointed unless proceedings and the person appointed are dismissed within
thirty (30) days; (v) insolvency within the meaning of Uniform Commercial Code Section 1-201 or failing generally to pay its debts as they become due within the meaning of Bankruptcy Code Title 11, Section 303(h)(1) (11 U.S.C.
§303(h)(1)), as amended; or (vi) certification in writing of its inability to pay its debts as they become due (and either party may periodically require the other to certify its ability to pay its debts as they become due) (collectively,
“Bankruptcy”); 
 (b) Failure to pay any amount due and such failure continues five (5) days after written notice; or 

(c) Failure to perform any other material obligation of this Agreement or any other agreement now or hereafter entered into between the parties and such
failure continues for thirty (30) days after it receives notice of such breach from the non-breaching party; provided, however, if the other party has commenced to cure such breach within such thirty (30) days, but is not reasonably able
to complete it within such thirty (30) days, such party will have a reasonable time to complete its cure if it diligently pursues the cure until completion. “For cause” does not include Customer’s receiving a more favorable offer
from an ABDC competitor. 
 5.2 Termination Upon PMC Change-in-Control. On and subject to the requirements of Paragraph 9.3(b), in
addition to other available remedies, ABDC may terminate this Agreement upon a Change-in-Control of PMC to which

 

  

					
	PMC – ABDC Amended and Restated PVA 1/1/2011	 	11	 	

 
ABDC does not provide its prior written consent by providing PMC and its Assignee with reasonable prior written notice of not less than ninety (90) days from the consummation of PMC’s
Change-in-Control. 
 5.3 Survival Upon Termination. Within five (5) days after expiration or earlier termination of this Agreement
for any reason, all amounts owed by Customer will be immediately due and payable, and Customer will (i) pay ABDC any amount owed and (ii) return to ABDC all hardware, Software and other equipment, including ordering devices and totes, or
pay to ABDC the replacement cost of such items that are not returned; provided, however, if this Agreement is terminated by Customer due to a default by ABDC, any such payments will be due as otherwise provided in this Agreement. Obligations in
Provisions Paragraphs 4, 5, 6 and 9 and any provision the context of which shows the parties intended it to survive will remain in effect after the Term. 
 6. INDEMNIFICATION 
 Each party (“Indemnifying Party”) will indemnify and defend
the other, its employees and representatives (“Indemnified Party”) against all claims and damages (including expenses and attorneys’ fees) (“Claim”) to the extent arising out of Indemnifying Party’s obligations under
this Agreement. Failure to give prompt written notice of a Claim will not relieve Indemnifying Party of liability except to the extent caused by such failure. Indemnifying Party will defend a Claim with counsel reasonably satisfactory to Indemnified
Party and Indemnified Party will cooperate fully in such defense. 
 7. CUSTOMER’S INSURANCE 

Customer will maintain sufficient insurance to cover all unpaid inventory in its possession. Customer will maintain professional liability insurance with
limits of no less than $* per incident and $* aggregate. 
 8. SOFTWARE LICENSE 
 8.1 License. ABDC grants Customer a non-exclusive, nontransferable and revocable license to use software and related documentation ABDC provides for use in the Program (“Software”).
Customer may not make, or allow others to make, copies except one backup copy. Customer must include all proprietary notices in permitted copies. Customer may not modify Software or create derivative works and may not translate, reverse engineer,
disassemble or decompile Software. 
 8.2 Limited Warranty. ABDC warrants that (i) Software will perform substantially in accordance
with its documentation if operated as directed; (ii) hardware provided by ABDC and diskettes, CD-ROMs or other media on which the Software is provided will be free from defects under normal use; and (iii) Software will not infringe the
rights of any third party. ABDC DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING THOSE OF MERCHANTABILITY, AND FITNESS FOR A PARTICULAR PURPOSE, FOR HARDWARE AND SOFTWARE, AND ACCURACY OF ANY DATA. ALL DATA IS PROVIDED “AS
IS.” DUE TO THE NATURE OF SOFTWARE, HARDWARE AND DATA, ERRORS AND INTERRUPTIONS MAY OCCUR AND CUSTOMER HAS ALL RISKS FOR QUALITY AND PERFORMANCE. No oral or written information provided by ABDC, its employees or other representatives will
create any warranty. 
 8.3 Remedy. ABDC’s liability and Customer’s exclusive remedy for breach of warranties in Paragraph 8.2
will be, at ABDC’s option, to (i) repair or replace Software or hardware so it performs substantially in accordance with its documentation and is non-infringing; (ii) advise Customer how to achieve substantially the same functionality
using different procedures, or (iii) replace defective media that is returned. 
 9. MISCELLANEOUS 

9.1 Force Majeure. If ABDC’s performance is prevented, delayed or otherwise adversely affected by labor disputes, fire, terrorism, acts of God
or any other cause beyond its control, including unavailability of Products, transportation, materials or fuel, delays by suppliers, loss of facilities, internet, telecommunication or electrical system failures or interruptions, voluntary foregoing
a right in order to comply with or accommodate government orders or requests, compliance with any law or any other cause beyond its control (“Force Majeure”), (i) ABDC may reduce or eliminate Products without liability or obligation
during the Force Majeure period and (ii) to the extent ABDC reduces or eliminates Products, Customer shall not be required to maintain ABDC as the Primary Vendor of all requirements of Customer’s Facilities for Products during the Force
Majeure period. In addition, if Force Majeure affects ABDC’s cost of operations and Customer elects to utilize ABDC as a vendor for Products to Customer’s Facilities during the Force Majeure period (provided that Customer shall not be
required to maintain ABDC as a Primary Vendor to such extent),

 
ABDC may, at its discretion, add to the price of Products all of its increased costs, including taxes, so long as Force Majeure affects such costs. 

9.2 Assignment. (a) All covenants, promises and agreements in this Agreement inure to the benefit of and are binding upon the successors and
permitted assigns of each party. In no event will an agreement between a successor to or permitted assign of Customer and any third party negate or diminish in any way such successor’s or assign’s obligations under this Agreement.

 (b) Neither party may assign its rights or delegate its duties under this Agreement, including by asset sale or upon a Change-in-Control,
without the prior written consent of the other party, which consent shall not be unreasonably withheld, it being understood that ABDC shall not be considered to be acting unreasonably in the case of such a sale or Change-in-Control of PMC if the
requirements of Paragraph 9.2(c) are not satisfied or if the proposed Assignee of PMC following such sale or Change-in-Control does not have sufficient financial capability to satisfy the obligations of this Agreement, applying reasonable industry
credit standards. In the event that ABDC does not consent to any assignment (or deemed assignment) or delegation occurring upon a PMC Change-In-Control that nonetheless is consummated, the Agreement shall nevertheless remain in effect for a
reasonable period of time of not less than ninety (90) days following the PMC Change-in-Control to permit the Assignee of PMC to transition to a different drug purchasing contract without in any manner limiting ABDC’s remedies or rights
against PMC or PMC’s Assignee pursuant to the Agreement. Each party hereby consents to the other party assigning part or all of its obligations to any affiliate; provided, however, any assignment will not relieve a party of its performance
obligations under this Agreement. 
 (c) Notwithstanding anything to the contrary in this Agreement, in the event of such an assignment,
delegation or Change-in-Control by or of PMC, or a sale or transfer of ownership or control of any Facility (subject to the Facility Sale exception set forth below), PMC shall provide ABDC with prior written notice thereof and shall cause the
surviving entity, successor-in-interest or transferee, as the case may be (the “Assignee”), to either (1) agree to be bound by the terms of this Agreement from and after the date of such event or (2) enter into a
replacement agreement to this Agreement with ABDC on such terms as are reasonably acceptable to ABDC and the Assignee; provided, however, that in the event of a PMC Change-in-Control, an Assignee consented to by ABDC will be permitted to terminate
this Agreement as follows: (x) if there is more than one (1) year remaining until the end of the then current Term, the approved Assignee may terminate this Agreement without cause for any or no reason at any time on or after the one
(1) year anniversary of the Change-in-Control upon at least sixty (60) days prior written notice to ABDC; or (y) if there is less than one (1) year remaining until the end of the then current Term, the approved Assignee may
terminate this Agreement in accordance with Section 7.B. of this Agreement and the termination shall be effective on the last day of the then current Term. In addition, Customer may sell a Facility, or multiple Facilities in one or more
transactions (“Facility Sale”), and only be required to provide ABDC written notice of such transaction(s) (without causing the Assignee to satisfy the additional requirements set forth above), so long as the collective Net Purchase
volume of all such Facilities sold, taking into account all prior Facility Sales, represents less than 10% of Customer’s annual Net Purchase volume as of the Effective Date, which the parties benchmark at $1,200,000,000.00. In the event of a
Facility Sale that is attributable towards the 10% threshold noted above, unless otherwise agreed to by the parties, this Agreement shall terminate with respect to any Facility which is the subject of the Facility Sale. 

(d) With respect to PMC, “Change-in-Control” shall mean the occurrence of one or more of the following: 

(i) the acquisition by any person (or related group of persons), whether by tender or exchange offer made directly to PMC’s stockholders, open
market purchases or any other transaction or series of transactions possessing sufficient voting power in the aggregate to elect a majority of PMC’s board of directors (“Board”); 

(ii) a merger or consolidation in which PMC is not the surviving entity, except for a transaction in which securities representing more than fifty
percent (50%) of the total combined voting power of the surviving entity are held by persons who held common stock immediately prior to such merger or consolidation and those members of the existing Board constitute a majority of the Board
immediately after such merger or consolidation; 

 

  

					
	PMC – ABDC Amended and Restated PVA 1/1/2011	 	12	 	

 (iii) any reverse merger in which PMC is the surviving entity but in which either securities representing
more than fifty percent (50%) of the total combined voting power of PMC’s outstanding securities are transferred to holders different from those who held such securities immediately prior to such merger or those members of the existing
Board do not constitute a majority of the Board immediately after such merger; or 
 (iv) the sale, transfer or other disposition of all or
substantially all of the assets of PMC. 
 (e) With respect to PCA or Chem Rx or a Facility, “Change-in-Control” means the sale
or transfer of 51% or more of the assets or voting equity of the respective entity or Facility to a person not wholly owned by PMC or to an affiliate of PMC of which PMC does not have at least a 51% controlling interest. 

(f) Each party acknowledges that money damages would not be a sufficient remedy for any breach of restrictions under this Paragraph 9.2 and, if there is
a breach or threatened breach, the other party will be entitled to specific performance and injunctive or other equitable relief in addition to any other available remedies at law or in equity. 

9.3 EEO Requirements. ABDC warrants it does not and will not discriminate against any employee or applicant for employment because of race, creed,
color, national origin, religion, gender, sexual preference, veteran status, handicap or as otherwise may be prohibited by law and will meet affirmative action obligations as are imposed by law. 

9.4 Miscellaneous. The successful party in any legal action, including in a Bankruptcy proceeding, may recover all costs, including reasonable
attorneys’ fees. Pennsylvania law will govern this Agreement without reference to conflict of laws provisions. Any waiver or delay in enforcing this Agreement will not deprive a party of the right to act at another time or due to another
breach. All provisions are severable. In the event of a conflict between a prior document between the parties and this Agreement, this Agreement will control. This Agreement supersedes prior oral or written representations by the parties that relate
to its subject matter. Captions are intended for convenience of reference only. The parties may not modify this Agreement, or its Exhibits, other than by a subsequent writing signed by each party. This Agreement will be interpreted as if written
jointly by the parties. The parties are independent contractors. 
 9.5 Excluded Providers. The Office of Inspector General
(“OIG”) Special Advisory Bulletin on the Effect of Exclusions on Participation in Federal Health Care Programs clarifies OIG’s sanction authority to impose civil money penalties and deny reimbursement under federal health care
programs for products or services provided by an excluded entity. Specifically, it provides that “items or equipment sold by an excluded manufacturer or supplier used in the care or treatment of beneficiaries and reimbursed, directly or
indirectly, by a federal health care program violate the OIG’s exclusion.” ABDC certifies that neither it, nor any of its key personnel, are listed by a federal agency as being debarred, excluded, or otherwise ineligible for federal
program participation as of the Effective Date and ABDC will immediately notify Customer in writing if any of these events occurs. 
 9.6
HIPAA. This Agreement and certain data that may be exchanged under this Agreement may be subject to (i) the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) and ABDC may be a “business associate”
of Customer for purposes of HIPAA and the rules and regulations promulgated under HIPAA and (ii) the Confidentiality of Medical Information Act (California Civil Code Sections 56.10 et seq.) (the “Medical Information
Act”). The parties will amend this Agreement, if and to the extent required, to comply with HIPAA and the Medical Information Act, including provisions relating to written contracts among business associates.

 
 

  

					
	PMC – ABDC Amended and Restated PVA January 1, 2011	 	13	 	

 EXHIBIT 4 TO 
 AMENDED AND RESTATED PRIME VENDOR AGREEMENT 
 ABDC’S * RETURNS
POLICY 
 ABDC will comply with the Prescription Drug Marketing Act of 1987, as well as all state PDMA regulations, with regard to
Customer’s return of prescription drugs. Credit for a returned Product will not exceed Customer’s original acquisition price. 

Returnable Product 
 1. Product
originally purchased from ABDC and returned in saleable condition within * days of invoice date will be credited at *% of Customer’s original acquisition price. Saleable Products are those that ABDC reasonably determines can be resold back into
the marketplace in the normal course of business and must (i) be in original condition with no defects or adulteration in packaging; (ii) be unopened with seals intact; (iii) have at least * months (current month plus * dating
remaining before expiration; (iv) have been stored and transported under proper conditions while in custody of Customer; and (v) have been sold by ABDC to Customer in the ordinary course (e.g., not in a special sale or subject to
conditions that restrict returns). 
 2. Product originally purchased from ABDC and returned in saleable condition beyond * days of the date of
the invoice provided will be credited at *% of Customer’s *. 
 3. Product originally purchased from ABDC and returned in non-saleable
condition but that is accepted for return by the manufacturer will be credited at *% of the estimated value received from the manufacturer, less a *. 
 4. Products that was damaged prior to its delivery by ABDC to Customer and for which damage was promptly reported to ABDC will be credited at *% of Customer’s original acquisition price. 

5. Products originally purchased from ABDC and recalled by any governmental authority or by the manufacturer of such products will be credited at *% of
the applicable manufacturer credit. 
 Non-Refundable Product 
 The following Product will not be accepted for credit: 
 1. Class II and Class IIN controlled
substances; 
 2. Open packages, partial bottles, broken seals, or any other product not returned in unopened original packaging, except for
manufacturing recalls and products damaged prior to delivery to Customer; 
 3. Products whose manufacturer requires direct or third-party
return, except in the case of Product mis-shipments or mis-orders if reported within 5 business days of receipt; 
 4. Products sold as
non-returnable by the manufacturer or ABDC, including any Product subject to a Florida or other pedigree. 
 Schedule Item Returns

 Return of scheduled items (other than Schedule II and IIN) must be pre-approved by ABDC’s distribution center. Scheduled drug returns
must be packed separately from other returns and proper procedures must be followed to ensure compliance with current law, including CFR Part 21. Schedule items returned in violation of this policy will receive no credit. 

Hazardous Substances Returns 
 Return of
hazardous substances must be pre-approved by ABDC’s distribution center. Hazardous substance returns must be clearly marked and packed separately from other returns. Hazardous substances returned in violation of this policy will receive no
credit. 
 Temperature Control Returns 
 Items requiring temperature control during shipment must be called in to customer service/returned goods department for return authorization. 
 Electronic Credit & Return Requests 
 Returns are typically processed within * days
of ABDC’s receipt of return request. Credit and return requests should be entered electronically to assure proper and prompt credit. Echo credit entry should be used for ordering errors, defectives, outdated, and overstocked items. Requests for
credits involving billing errors, damaged in shipment, shortages, and filling errors must be phoned into the ABDC customer service/returned goods department at ABDC’s distribution center serving Customer’s Facility. 

PDMA Certification 
 To receive credit, a
signed and dated PDMA return certification must accompany all prescription drug returns. A sample return certification follows: 

I certify that the pharmaceutical products being returned are saleable and have been stored and maintained while in our possession in
accordance with the manufacturer’s temperature and storage requirements listed on the packaging and in accordance with the requirements listed in the current edition of USP/NF. I further certify that this product has not been transferred to
this facility from another location and that I am able to certify as to the product’s proper storage and condition. 
 NOTE: This Policy is
subject to change from time to time, in ABDC’s sole discretion, and such changes will be effective * days after notice is provided to Customer. Any such changes by ABDC that are applicable to Customer will be non-discriminatory, generally
applicable to ABDC’s customers, and consistent with the terms of this Agreement. 

  

					
	PMC – ABDC Amended and Restated PVA January 1, 2011	 	14	 	

 EXHIBIT 5 TO 
 AMENDED AND RESTATED PRIME VENDOR AGREEMENT 
 DEFINITIONS

 ABDC Special Price Products means Services and Products designated * by ABDC that are not be *, but instead are * for such
Products and Services, including but not limited to *. 
 AMP means average manufacturer price, as defined by applicable law and the
Department of Health and Human Services. 
 Branded Rx means prescription pharmaceutical products that are manufactured by an exclusive
source and are patent protected. 
 Contract Product means a Product encompassed by a pricing agreement between Customer, or
Customer’s GPO, and the applicable manufacturer of such Product. 
 Contract Year means each 12-month period commencing on the
Effective Date and the annual anniversary of the Effective Date. 
 Cost means (a) with respect to any * Product, the price of the
Product *, and (b) with respect to any * Product, the price of the Product *, in either case *given to ABDC by its manufacturers. 

CSOS means the DEA’s controlled substance ordering system. 
 Customer has the meaning ascribed to that term in the Agreement preamble. 
 DEA
means the United States Drug Enforcement Agency. 
 DME means home healthcare/durable medical equipment items. 

EFT means Electronic Funds Transfer. 

Emergency Order means an unscheduled delivery of Rx (only) in response to a possible loss of life or other critical care situation. 

Facility means (a) each of Customer’s LTCPs as of the Effective Date, and (b) any other LTCP pharmacy in the United States that,
during the Term and subject to ABDC’s credit approval and policies (i) Customer acquires (directly or through a commonly controlled, owned or managed affiliate or subsidiary); (ii) Customer controls, directly or indirectly; or
(iii) Customer or any other Facility (as denoted above) operates or manages, provided, however, that any newly acquired pharmacy with an existing agreement with another distributor will become a Facility under this Agreement upon the earlier of
expiration of such existing agreement or the date Customer (or such affiliate or subsidiary) may terminate such agreement according to its terms, with or without cause, without breaching it or paying a termination penalty. For the avoidance of
doubt, a Facility excludes any pharmacy under Customer’s control that serves as a hospital pharmacy. 
 GCN means generic chemical
number and is a number assigned by First Data Bank. 
 Generic Rx means generic prescription pharmaceutical products that are equivalent
to Brand Rx. 
 GPO means a Group Purchasing Organization. 
 HBC means health and beauty care items. 
 Injectable means Rx that is administered
intravenously or by injection, including vials, ampoules, pre-filled syringes, mini-bags and small and large volume IV fluids, kits and carpuject. 
 LTCP means long term care pharmacy. 
 Net Purchase(s) means Customer’s total
purchases, less returns, credits, rebates, late payment fees and similar items. 

  

					
	PMC – ABDC Amended and Restated PVA January 1, 2011	 	15	 	

 OTC means over-the-counter pharmaceuticals (non-prescription). 

Outsourcing Fee has the meaning ascribed to that term in Paragraph 2(C) of Exhibit 1. 
 Price of Goods means * that Customer * to ABDC for Products and Services *. 
 Primary
Vendor means Customer purchases from ABDC no less than 98% of all Brand Rx that Customer purchases from any source, including, without limitation, Products purchased from ABDC pursuant to Customer’s direct contracts with pharmaceutical
manufacturers that are administered by ABDC pursuant to Paragraph 1(E) of Exhibit 1. 
 Products mean Rx (Branded Rx and Generic Rx), OTC
and nutritional, HBC and DME items. 
 Program means the overall arrangement encompassed by this Agreement pursuant to which ABDC will
provide Products and Services to Customer. 
 PRxO Contract Cost means *of PRxO Generics *. 

PRxO Generics means Generic Rx available under the PRxO Generics Purchase Program. 
 PRxO Generics Purchase Program means ABDC’s proprietary Generic Rx formulary purchase *. 
 PRxO Rebates mean the * paid to * by * of PRxO Generics, excluding any * and any * paid to * by the *. 
 Rx means Branded Rx and Generic Rx. 
 Services mean, collectively, the services
provided by ABDC to Customer pursuant to this Agreement in connection with ABDC’s distribution of Products to Customer. 

  

					
	PMC – ABDC Amended and Restated PVA January 1, 2011	 	16	 	

 Exhibit 6 
 Form of Compliance Certificate 
 [Date] 
 Robert Mauch 
 Senior Vice President, Alternate Care Sales 

AmerisourceBergen Drug Corporation (“ABDC”) 
 1300 Morris Drive 
 Chesterbrook, PA 19087 

Dear Mr. Mauch: 
 In accordance with
Section 1(B) and Section 2(B) of the Amended and Restated Prime Vendor Agreement for Long Term Care Pharmacies (the “Agreement”) dated January 1, 2011, between PharMerica Corporation and certain of its affiliates
(“PharMerica”) and ABDC, I hereby attest that PharMerica has purchased from ABDC (i) at least 98% of all Branded Rx and (ii) no less than 95% of its non-Injectable Generic Rx during the calendar year that ended December 31,
            , and that PharMerica complied with the provisions of Section 1 and Section 2 of said year. 
 Sincerely, 
 PharMerica Corporation 

 

			
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

  

					
	PMC – ABDC Amended and Restated PVA January 1, 2011	 	17	 	

 [Date] 
 PharMerica Corporation 
 1901 Campus Place 
 Louisville, KY 40299 
 Dear
                    : 
 In
accordance with Paragraph 2(B) of Exhibit 1 of the Amended and Restated Prime Vendor Agreement for Long Term Care Pharmacies (the “Agreement”) dated January 1, 2011, between PharMerica Corporation and certain of its affiliates and
AmerisourceBergen Drug Corporation (“ABDC”), I hereby attest that ABDC passed through to PharMerica its prorate share of PRxO Rebates in accordance with the terms of the Agreement. 
 Sincerely, 
 AmerisourceBergen Drug Corporation 

 

			
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

  

					
	PMC – ABDC Amended and Restated PVA January 1, 2011	 	18	 	

 EXHIBIT 7 TO 
 AMENDED AND RESTATED PRIME VENDOR AGREEMENT 
 PURCHASING * CALCULATIONS

 A. PRxO Generic Rx Purchasing Threshold. As measured on a * basis no less than 95% of Customer’s total generic purchases,
based on * per Section 2.A. of Exhibit 1, will be PRxO purchases, where the calculation of the * shall be made according to the parameters so established at Table 1 of this Exhibit 7. With respect to Injectable Products, ABDC agrees to *.

 B. PRxO Generic Rx * Calculation: Not later than * days after the close of each *, ABDC and Customer will each calculate the PRxO
Generic Rx purchasing * and present to each other their findings in the following format. 
  

	*	calculation illustration (Figures are based on *): 

  

					
	 Total Generic Purchases
	  	$	 *	  
		
	 Excluded Purchases from total generic purchases
	  			
	 Products that are *
	  	$	 *	  
	 *
	  	$	 *	  
	 Purchases of *
	  	$	 *	  
	 Purchases of *
	  	$	 *	  
		  	 	 	 
	 Adjusted Total Generic Purchases
	  	$	 *	  
		
	 Total PRxO Purchases
	  	$	 *	  
		
	 Included as PRxO purchases
	  			
	 *Adjustment (est. *% of *)
	  	$	 *	  
	 Any Product that is available in the PRxO Generics Purchase Program that *and Customer *a PRxO Product
	  	$	 	  
		  	$	 	  
		  	 	 	 
	 Adjusted Total PRxO (Inclusions) Purchases
	  	$	 *	  
		
	 Adjusted Total PRxO Purchases
	  	$	 *	  
		
	 PRxO Purchasing * Rate
	  	 	*	% 

 For Illustration Purposes 

  

					
	PMC – ABDC Amended and Restated PVA January 1, 2011	 	19	 	

 TABLE 1 OF EXHIBIT 7 

TREATMENT OF GENERIC Rx PURCHASES 
  

																			
	 Types of
Purchases
	 	 Is GCN

listed in

PRxO

Catalogue
	 	 Is

Purchased

Through

ABC
	 	 PMC

Receives

*%

Discount
	 	 PMC Pays the

*% PRxO

Outsourcing

Fee
	 	 PMC

Receives

PRxO

Rebates
	 	
Is Included in 95% of Total
 Generic Purchases
 Calculation: Numeratori and
 Denominatorii
	 	
Is Included in 98% of Total
 Annual Rx Purchases:
 Numeratoriii and Denominatoriv

										
	*	 	YES	 	YES	 	NO	 	YES	 	YES	 	 Num
 Den
	 	 YES
 YES
	 	 Num
 Den
	 	 YES
 YES

										
	*	 	YES	 	YES	 	NO	 	YES	 	YES	 	 Num
 Den
	 	 NO
 NO
	 	 Num
 Den
	 	 YES
 YES

										
	*	 	YES	 	YES	 	NO	 	YES	 	YES	 	 Num
 Den
	 	 NO
 NO
	 	 Num
 Den
	 	 YES
 YES

										
	*	 	NO	 	YES	 	YES	 	NO	 	NO	 	 Num
 Den
	 	 NO
 NO
	 	 Num
 Den
	 	 YES
 YES

										
	*	 	NO	 	YES	 	NO	 	NO	 	NO	 	 Num
 Den
	 	 NO
 NO
	 	 Num
 Den
	 	 YES
 YES

										
	*	 	YES	 	YES	 	NO	 	YES	 	YES	 	 Num
 Den
	 	 YES
 YES
	 	 Num
 Den
	 	 NO
 NO

										
	*	 	NO	 	YES	 	YES	 	NO	 	NO	 	 Num
 Den
	 	 NO
 NO
	 	 Num
 Den
	 	 YES
 YES

										
	*	 	NO	 	YES	 	NO	 	NO	 	NO	 	 Num
 Den
	 	 NO
 NO
	 	 Num
 Den
	 	 YES
 YES

  

					
	PMC – ABDC Amended and Restated PVA January 1, 2011	 	20	 	

 TABLE 1 OF EXHIBIT 7 

TREATMENT OF GENERIC Rx PURCHASES 
  

																			
	 Types of
Purchases
	 	 Is GCN

listed in

PRxO

Catalogue
	 	 Is

Purchased

Through

ABC
	 	 PMC

Receives

*%

Discount
	 	 PMC Pays the

*% PRxO

Outsourcing

Fee
	 	 PMC

Receives

PRxO

Rebates
	 	
Is Included in 95% of Total
 Generic Purchases
 Calculation: Numeratori and
 Denominatorii
	 	
Is Included in 98% of Total
 Annual Rx Purchases:
 Numeratoriii and Denominatoriv

										
	*	 	YES	 	YES	 	NO	 	YES	 	YES	 	 Num
 Den
	 	 YES
 YES
	 	 Num
 Den
	 	 YES
 YES

										
	*	 	N/A	 	NO	 	NO	 	NO	 	NO	 	 Num
 Den
	 	 NO
 NO
	 	 Num
 Den
	 	 NO
 NO

										
	*	 	N/A	 	NO	 	NO	 	NO	 	NO	 	 Num
 Den
	 	 NO
 NO
	 	 Num
 Den
	 	 NO
 NO

										
	*	 	YES	 	YES	 	NO	 	YES	 	NO	 	 Num
 Den
	 	 YES
 YES
	 	 Num
 Den
	 	 YES
 YES

										
	*	 	YES	 	YES	 	YES	 	NO	 	NO	 	 Num
 Den
	 	 NO
 YES
	 	 Num
 Den
	 	 YES
 YES

										
	*	 	N/A	 	NO	 	NO	 	NO	 	NO	 	 Num
 Den
	 	 NO
 YES
	 	 Num
 Den
	 	 NO
 YES

										
	*	 	N/A	 	NO	 	NO	 	NO	 	NO	 	 Num
 Den
	 	 NO
 NO
	 	 Num
 Den
	 	 NO
 NO

  

					
	PMC – ABDC Amended and Restated PVA January 1, 2011	 	21	 	

 TABLE 1 OF EXHIBIT 7 

TREATMENT OF GENERIC Rx PURCHASES 

 

	i 	 The Numerator establishes the purchases that count as PRxO purchases. YES means the purchase counts as PRxO for the * calculation. NO means the
purchase does not count as PRxO for the * calculation. 

	ii	 The Denominator
establishes the purchases that count as Total Generic Purchases. YES means the purchase is included in the calculation of Total Generic Purchases. NO means the purchases is excluded in the calculation of Total Generic Purchases.

	iii	 The Numerator
establishes purchases that count as purchases from ABDC. YES means the purchase counts as a purchase from ABDC for the * calculation. NO means the purchase does not count as a purchase from ABDC for the * calculation. 

	iv	 The Denominator
establishes the purchases that count as Total Annual Rx Purchases. YES means the purchase is included in the calculation of Total Annual Rx Purchases. NO means the purchases is excluded in the calculation of Total Annual Rx Purchases.

	v	 Bulk Products mean
Products purchased by Customer * Products such as: *. 

  

					
	PMC – ABDC Amended and Restated PVA January 1, 2011	 	22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}]]